Lonza expands its HPAPI production capacity at its Switzerland facility after entering an agreement with AstraZeneca, and invests in manufacturing to establish efficiency.
Although the industry may not be among the ‘frontrunners’, Novo Nordisk is seeing the benefits when it comes to recruitment and developing mutually beneficial partnerships, says director.
Artificial intelligence tools will allow the pharmaceutical companies to make predictions about diseases more effectively than before, says ImaginAB’s CEO.
Civica signs a supply agreement with Xellia to manufacture antibiotics in the US, marking the organisation’s first step towards improving the availability of generics in short supply.
As WuXi STA expands its facility footprint in China, a VP of the company explains how global regulatory approvals fit with strategic plans for services to be concentrated geographically.
